For patients with PD-L1 CPS > 10 (Figure 4G), compared with chemotherapy alone, both immunotherapy combined with chemotherapy and double immunotherapy can significantly improve the OS of patients with advanced esophageal cancer, except for toripalimab + chemotherapy. The gene discussed is CD274; the disease is esophageal cancer.